Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection

被引:256
|
作者
Sugimura, Hiroshi
Nichols, Francis C.
Yang, Ping
Allen, Mark S.
Cassivi, Stephen D.
Deschamps, Claude
Williams, Brent A.
Pairolero, Peter C.
机构
[1] Mayo Clin, Div Gen Thorac Surg, Coll Med, Dept Hlth Sci Res, Rochester, MN 55905 USA
[2] Mayo Clin, Coll Med, Biostat Sect, Rochester, MN 55905 USA
来源
ANNALS OF THORACIC SURGERY | 2007年 / 83卷 / 02期
关键词
D O I
10.1016/j.athoracsur.2006.08.046
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Survival characteristics of patients who have recurrent nonsmall-cell lung cancer after surgical resection are not well understood. Little objective evidence exists to justify treatment for these patients. Methods. We prospectively followed 1,361 consecutive patients with nonsmall-cell lung cancer who underwent complete surgical resection at our institution from January 1997 to December 2001. Only patients having recurrent cancer were included in the analysis. Multivariable Cox proportional hazards models were used to evaluate the effect of prognostic factors on postrecurrence survival. Results. Follow-up was achieved in 1,073 patients, and recurrent cancer developed in 445. Complete information was available on 390 patients for analysis. There were 262 men and 128 women. Median age at time of recurrence was 69 years. Median time from surgical resection to recurrence was 11.5 months, and median postrecurrence survival was 8.1 months. Recurrence was intrathoracic in both in 47. Treatments after recurrence included surgery in 43 patients, chemotherapy in 59, radiation in 73, and a combination in 96. All patients who received treatment survived longer than those who received no treatment. Preoperative chemotherapy and postoperative radiotherapy for the primary lung cancer, poor Eastern Cooperative Oncology Group Performance Status, decreased disease-free interval from initial resection to recurrence, symptoms at recurrence, and certain location of recurrence significantly decreased postrecurrence survival. Conclusions. In our experience, treatment for recurrent nonsmall-cell lung cancer significantly prolongs survival. Various treatment modalities including surgery should be considered in patients with postoperative recurrent nonsmall-cell lung cancer. (c) 2007 by The Society of Thoracic Surgeons.
引用
收藏
页码:409 / 418
页数:10
相关论文
共 50 条
  • [31] Long term survival after pulmonary resection for stage I small cell lung cancer
    DellaPona, C
    Massera, F
    Tondini, M
    Robustellini, M
    Rossi, G
    Rocco, G
    Vertemati, G
    Meroni, A
    Rizzi, A
    INTERNATIONAL CONGRESS OF THORAX SURGERY, 1997, : 325 - 329
  • [32] Positron emission tomography imaging in nonsmall-cell lung cancer
    Erasmus, Jeremy J.
    Macapinlac, Homer A.
    Swisher, Stephen G.
    CANCER, 2007, 110 (10) : 2155 - 2168
  • [33] HYDRAZINE SULFATE IN NONSMALL-CELL LUNG-CANCER - REPLY
    PIANTADOSI, S
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (06) : 1118 - 1118
  • [34] Dihydropyrimidine dehydrogenase levels in nonsmall-cell lung cancer tissues
    Yano T.
    Koga T.
    Ninomiya S.
    Takeo S.
    International Journal of Clinical Oncology, 2002, 7 (6) : 361 - 364
  • [35] Recent developments in the chemotherapeutic options for nonsmall-cell lung cancer
    Ibrahim, M. Nazir
    Abdullah, Zarina
    Martin, Michael J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (10) : 1397 - 1410
  • [36] IS CHEMOTHERAPY FOR METASTATIC NONSMALL-CELL LUNG-CANCER WORTH IT
    RUCKDESCHEL, JC
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (08) : 1293 - 1296
  • [37] A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer
    Wu, Yin
    Biswas, Dhruva
    Usaite, Ieva
    Angelova, Mihaela
    Boeing, Stefan
    Karasaki, Takahiro
    Veeriah, Selvaraju
    Czyzewska-Khan, Justyna
    Morton, Cienne
    Joseph, Magdalene
    Hessey, Sonya
    Reading, James
    Georgiou, Andrew
    Al-Bakir, Maise
    Birkbak, Nicolai J.
    McGranahan, Nicholas
    Jamal-Hanjani, Mariam
    Hackshaw, Allan
    Quezada, Sergio A.
    Hayday, Adrian C.
    Swanton, Charles
    NATURE CANCER, 2022, 3 (06) : 696 - +
  • [38] The Mediastinoscopy and the Future in Nonsmall-Cell Lung Cancer Staging Reply
    Sivrikoz, C. M.
    Ak, I.
    THORACIC AND CARDIOVASCULAR SURGEON, 2012, 60 (02): : 123 - 123
  • [39] Random forests to predict survival of octogenarians with brain metastases from nonsmall-cell lung cancer
    Lijun Song
    Yu Wang
    Xue Li
    Yi Liu
    Bingyi Yin
    Daorui Li
    Hongsheng Lin
    Yuqi Zhang
    Brain Science Advances, 2024, 10 (01) : 39 - 56
  • [40] Cost-effectiveness of chemotherapy for nonsmall-cell lung cancer
    Dranitsaris, G
    Cottrell, W
    Evans, WK
    CURRENT OPINION IN ONCOLOGY, 2002, 14 (04) : 375 - 383